Ocular Therapeutix (OCUL) Q2 2024 earnings summary

Executive summary

• Leadership transition in April set a new vision to focus on retina and accelerate execution, prioritizing AXPAXLI for wet AMD.

• Accelerated enrollment in SOL-1 Phase 3 and rapid initiation of SOLAR/SOL-R registrational studies for AXPAXLI in wet AMD, with FDA confirmation of both as registration-enabling.

• Positive 48-week HELIOS Phase I data in NPDR showed DRSS improvement and no vision-threatening complications, presented as a late breaker at ASRS.

• Strategic restructuring in May 2024 reduced workforce by 13% to prioritize AXPAXLI, incurring $1.6 million in charges.

• Company is well-financed with $459.7 million in cash as of June 30, 2024, providing a runway into 2028 and fully funding pivotal studies.

Financial highlights

• Q2 2024 net revenue was $16.4 million, up 8.3% year-over-year, driven by DEXTENZA sales.

• Q2 2024 net loss was $43.8 million, compared to $20.7 million in Q2 2023, with higher R&D and G&A expenses.

• Operating expenses for Q2 2024 totaled $60.0 million, up $24.3 million year-over-year, mainly from R&D and G&A increases.

• Cash and cash equivalents stood at $459.7 million as of June 30, 2024.

• Interest income rose to $6.0 million in Q2 2024, reflecting higher cash balances and rates.

Outlook and guidance

• Existing cash is expected to fund operations, debt service, and capital expenditures into 2028.

• SOL-1 enrollment progressing faster than expected; official guidance for completion remains end of Q1 2025.

• Full-year 2024 DEXTENZA net revenue expected between $62.0 million and $67.0 million.

• Anticipates increased R&D expenses as AXPAXLI Phase 3 trials progress.

• G&A expenses expected to decrease short term due to restructuring, but rise longer term as teams expand.